Eli Lilly Overview
- Year Founded
-
1876

- Status
-
Public
- Employees
-
47,000

- Stock Symbol
-
LLY

- Investments
-
194
- Share Price
-
$771.71
- (As of Friday Closing)
Eli Lilly General Information
Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact Information
Website
www.lilly.comCorporate Office
- Lilly Corporate Center
- Indianapolis, IN 46285
- United States
Corporate Office
- Lilly Corporate Center
- Indianapolis, IN 46285
- United States
Eli Lilly Timeline
Eli Lilly Stock Performance
As of 18-Jul-2025, Eli Lilly’s stock price is $771.71. Its current market cap is $693B with 898M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$771.71 | $761.50 | $677.09 - $972.53 | $693B | 898M | 3.91M | $12.34 |
Eli Lilly Financials Summary
As of 31-Mar-2025, Eli Lilly has a trailing 12-month revenue of $49B.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 771,958,720 | 721,953,716 | 571,131,575 | 360,855,183 |
Revenue | 49,003,200 | 45,042,700 | 34,124,100 | 28,541,400 |
EBITDA | 16,096,200 | 15,052,400 | 8,394,200 | 8,597,700 |
Net Income | 11,106,400 | 10,590,000 | 5,240,400 | 6,244,800 |
Total Assets | 89,388,800 | 78,714,900 | 64,006,300 | 49,489,800 |
Total Debt | 38,515,900 | 33,644,200 | 25,225,300 | 16,238,600 |
Eli Lilly Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Eli Lilly Comparisons
Industry
Financing
Details
Eli Lilly Competitors (25)
One of Eli Lilly’s 25 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
AbbVie | Corporation | North Chicago, IL | ||||
Pfizer (Pharmaceuticals) | Corporation | New York, NY | ||||
Merck & Co. | Corporation | Rahway, NJ |
Eli Lilly Patents
Eli Lilly Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20250197413-A1 | Rxfp1 receptor agonists | Pending | 15-Dec-2023 | ||
US-20250205352-A1 | Compositions and methods for modulating nav1.8 | Pending | 13-Dec-2023 | ||
US-20250197493-A1 | Lag-3 agonist antibodies | Pending | 13-Dec-2023 | ||
US-20250163119-A1 | Compounds for the treatment of diabetes or obesity | Pending | 17-Nov-2023 | ||
US-D1084128-S1 | Label | Active | 06-Nov-2023 |
Eli Lilly Signals
Eli Lilly Investments & Acquisitions (194)
Eli Lilly’s most recent deal was a Seed Round with Laverock Therapeutics for . The deal was made on 30-Jun-2025.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Laverock Therapeutics | 30-Jun-2025 | Seed Round | Biotechnology | ||
Verve Therapeutics | 17-Jun-2025 | Merger/Acquisition | Drug Discovery | ||
Signify Bio | 06-Jun-2025 | Early Stage VC | Biotechnology | ||
Camurus (Worldwide Rights in Lund, Sweden) | 03-Jun-2025 | Corporate Asset Purchase | Buildings and Property | ||
SiteOne Therapeutics | 27-May-2025 | Merger/Acquisition | Drug Discovery |
Eli Lilly ESG
Risk Overview
Risk Rating
Updated July, 01, 2025
23.36 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile

Pharmaceuticals
Industry
of 847
Rank
Percentile

Pharmaceuticals
Subindustry
of 420
Rank
Percentile

Eli Lilly Exits (46)
Eli Lilly’s most recent exit was on 01-Feb-2024 from BioAge Labs. The exit was categorized as with 15 buyers.
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
BioAge Labs | 01-Feb-2024 | Completed |
|
||
Foghorn Therapeutics | 13-Dec-2021 | Completed |
|
||
Cedilla Therapeutics | 25-Oct-2021 | Completed |
|
||
Acrivon Therapeutics | 29-Jun-2021 | Completed |
|
||
DTx Pharma | 21-Mar-2021 | Later Stage VC | Completed |
|
Eli Lilly Affiliates
Subsidiaries (13)
Name | Industry | Location | Year Founded |
---|---|---|---|
Versanis Bio | Oakland, CA | 2020 | |
Prevail Therapeutics | New York, NY | 2017 | |
Akouos | Boston, MA | 2016 | |
Aparito | Wrexham, United Kingdom | 2014 | |
Protomer Technologies | Pasadena, CA | 2014 |
Eli Lilly FAQs
-
When was Eli Lilly founded?
Eli Lilly was founded in 1876.
-
Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, IN.
-
What is the size of Eli Lilly?
Eli Lilly has 47,000 total employees.
-
What industry is Eli Lilly in?
Eli Lilly’s primary industry is Pharmaceuticals.
-
Is Eli Lilly a private or public company?
Eli Lilly is a Public company.
-
What is Eli Lilly’s stock symbol?
The ticker symbol for Eli Lilly is LLY.
-
What is the current stock price of Eli Lilly?
As of 18-Jul-2025 the stock price of Eli Lilly is $771.71.
-
What is the current market cap of Eli Lilly?
The current market capitalization of Eli Lilly is $693B.
-
What is Eli Lilly’s current revenue?
The trailing twelve month revenue for Eli Lilly is $49B.
-
Who are Eli Lilly’s competitors?
Amgen, Bristol-Myers Squibb, AbbVie, Pfizer (Pharmaceuticals), and Merck & Co. are some of the 25 competitors of Eli Lilly.
-
What is Eli Lilly’s annual earnings per share (EPS)?
Eli Lilly’s EPS for 12 months was $12.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »